RECORD // Company

Acrivon Therapeutics, Inc.

Built 2026-11-21T11:33:04Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Acrivon Therapeutics · Ctgov · exact name match to 'Acrivon Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • ACRIVON THERAPEUTICS INC · Epa echo · same registered legal name as 'Acrivon Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001193125-26-463419

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-17,897,0003 months ended 2026-09-3010-Q2026-11-160001193125-26-4634192026-11-21 11:33 UTCReport an error
Cash and cash equivalents$47,535,000at 2026-09-3010-Q2026-11-160001193125-26-4634192026-11-21 11:33 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001781174
Ticker
ACRV
EIN
825125532
CUSIP
004890109
Record ID
sx:sec:0001781174

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

31 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-21 11:33 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-20SEC EDGAR company profile2026-11-21 11:33 UTCReport an error
Fiscal year end (MMDD)12312026-11-20SEC EDGAR company profile2026-11-21 11:33 UTCReport an error
Business address480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 024722026-11-20SEC EDGAR company profile2026-11-21 11:33 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-21 11:33 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-77,905,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:33 UTCReport an error
Total assets (at 2025-12-31)$129,717,0002025-12-3110-K, XBRL Assets2026-11-21 11:33 UTCReport an error
Stockholders' equity (at 2025-12-31)$112,516,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:33 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$41,499,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:33 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-63,665,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:33 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$1,669,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:33 UTCReport an error
Operating lease liabilities (at 2025-12-31)$2,709,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:33 UTCReport an error
Form D total offering amount (D filed 2021-11-23)$99,999,9742021-11-23D2026-11-21 11:33 UTCReport an error
Form D total amount sold (D filed 2021-11-23)$99,999,9742021-11-23D2026-11-21 11:33 UTCReport an error
Form D industry groupBiotechnology2021-11-23D2026-11-21 11:33 UTCReport an error
Form D revenue rangeDecline to Disclose2021-11-23D2026-11-21 11:33 UTCReport an error
Form D date of first sale2021-11-092021-11-23D2026-11-21 11:33 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-20)On November 20, 2026, at the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain, Dr. Timothy A. Yap, MBBS, Ph.D., FRCP, of The University of Texas MD Anderson Cancer Center presented a late-breaker oral plenary presentation that showed results from the dose escalation phase of the Company’s ACR-2316 Phase 1/2 trial (the “38th EORTC-NCI-AACR Symposium Deck”). A Copy of the Deck is attached hereto as Exhibit 99.1, and is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K. The Company also posted a copy of the Deck to the “Science & Publications” section of the Company’s website at www.acrivon.com. The information in this Item 7.01, including Exhibit 99.1 attached…2026-11-20SEC EDGAR 8-K 0001193125-26-470245 (text as filed, excerpt)2026-11-21 11:33 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-16)On November 16, 2026, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended September 30, 2026, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company…2026-11-16SEC EDGAR 8-K 0001193125-26-463444 (text as filed, excerpt)2026-11-21 11:33 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-10)On November 10, 2026, Acrivon Therapeutics, Inc. (the “Company”) hosted a webcast corporate R&D event with Eosinophilic esophagitis (EoE) Key Opinion Leaders to discuss Acrivon’s new immunology and inflammation (I&I) programs, acquired using its AI-driven AP3 platform. The webcast took place from approximately 4:00 p.m. to 5:00 p.m. ET. The agenda featured a presentation by the Company’s leadership team introducing the ACR-525 and PKCθ inhibitor preclinical programs and initial development plans in EoE, followed by an overview of EoE epidemiology and unmet need by Dr. Arjan Bredenoord (principal investigator and professor, Gastroenterology and Hepatology, Amsterdam University Medical…2026-11-10SEC EDGAR 8-K 0001193125-26-455669 (text as filed, excerpt)2026-11-21 11:33 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-06)On November 6, 2026, Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), announced that it has entered into an asset purchase agreement (the “Purchase Agreement”) with Aqilion AB, an unlisted Swedish public limited company (AB (publ); Sw. aktiebolag), registration number 556623-2095 (“Aqilion”), pursuant to which the Company has acquired Aqilion’s programs for the discovery, research and development of oral JAK1 inhibitors, including ACR-525 (formerly known as AQ280), and PKCθ inhibitor preclinical program, for the potential treatment of inflammatory or autoimmune diseases (collectively, the “Acquired Assets”), together with certain related assets (the “Transaction”). As…2026-11-06SEC EDGAR 8-K 0001193125-26-450779 (text as filed, excerpt)2026-11-21 11:33 UTCReport an error
Largest institutional holder #1 (13F as filed): RA CAPITAL MANAGEMENT, L.P.$21,768,3252026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #2 (13F as filed): Sands Capital Alternatives, LLC$4,074,9022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$1,694,5742026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #4 (13F as filed): WELLINGTON MANAGEMENT GROUP LLP$1,580,8712026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #5 (13F as filed): RENAISSANCE TECHNOLOGIES LLC$1,350,7762026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #6 (13F as filed): TWO SIGMA INVESTMENTS, LP$1,141,8662026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #7 (13F as filed): MARSHALL WACE, LLP$946,7042026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #8 (13F as filed): BRIDGEWAY CAPITAL MANAGEMENT, LLC$674,4422026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #9 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$472,2732026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #10 (13F as filed): BlackRock, Inc.$425,6202026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.